The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06007014
Recruitment Status : Not yet recruiting
First Posted : August 23, 2023
Last Update Posted : September 13, 2023
Sponsor:
Information provided by (Responsible Party):
Yanbing Li, Sun Yat-sen University

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The goal of this clinical trial is to evaluate the Efficacy and Safety of Chiglitazar Added to Patients with type 2 diabetes who do not respond well to metformin combined with insulin glargine. The main question it aims to answer are:

• T2DM patients still cannot effectively control their blood sugar with the combination of insulin and metformin. The combination of follow-up treatment and hypoglycemic drugs is worth exploring, and it is necessary to explore and confirm the combination of effective and safe drugs for insulin resistance on the basis of the above treatment plans.

Participants will be asked to receive either Chiglitazar or placebo in addition to metformin and insulin glargine 18 weeks.

Researchers will compare placebo groups to see if the effective effect and safety indicators of Chiglitazar for reducing insulin dosage, lowering blood sugar, regulating blood lipids.


Condition or disease Intervention/treatment Phase
Efficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM Patients Metformin Combined With Insulin Glargine in the Treatment of Type 2 Diabetes Patients Who Still Have Poor Hypoglycemic Effect 128 Patients Were Randomly Assigned 1:1 Metformin and Insulin Glargine Combined With Chiglitazar Sodium Tablets 48mg/ Day Group Metformin and Insulin Glargine Combined With Placebo Group InvestigatorInitiate Trial Changes in HbA1C From Baseline at 18 Weeks of Treatment Drug: Chiglitazar sodium Drug: Chiglitazar placebo Not Applicable

Detailed Description:

T2DM patients using insulin combined with metformin dual therapy regimen, still can not have effective control of blood sugar, the combination of follow-up treatment and hypoglycemic drugs is worth exploring, and it is necessary to base on the above treatment plans to explore and confirm the treatment of effective and safe drugs for insulin resistance. This study investigated the efficacy and safety of metformin combined with insulin glargine in the treatment of type 2 diabetes mellitus (T2DM) in patients who still have poor hypoglycemic effect, plus Chiglitazar 48mg/ day for 18 weeks.

A total of 128 patients were expected to be included, and were randomly assigned 1:1 to the combination of metformin and insulin glargine combined with Chiglitazar sodium tablet 48mg/ day group. Metformin and insulin glargine combined with placebo group.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 128 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Metformin and insulin glargine combined with Chiglitazar sodium tablets 48mg/ day group；Metformin and insulin glargine combined with placebo group.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-Center, Randomised, Double-blind, Placebo Parallel Controlled Clinical Study to Evaluate the Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes
Estimated Study Start Date : October 31, 2023
Estimated Primary Completion Date : October 30, 2025
Estimated Study Completion Date : December 30, 2025

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Intervention group
Metformin and insulin glargine combined with sitaglitat sodium tablets 48mg/ day group;
 Drug: Chiglitazar sodium
tablets 48mg/ day administered for 18 weeks
Placebo Comparator: Placebo group
Metformin and insulin glargine combined with placebo group
 Drug: Chiglitazar placebo
tablets 48mg/ day administered for 18 weeks


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. HbA1C [ Time Frame: 18 weeks of treatment ]
    Changes in HbA1C from baseline


Secondary Outcome Measures :
  1. Insulin [ Time Frame: 6 weeks and 18 weeks of treatment ]
    Changes in the daily dose of insulin from baseline

  2. Triglyceride [ Time Frame: 18 weeks of treatment ]
    Changes in the daily dose of triglyceride from baseline

  3. Fasting blood glucose [ Time Frame: 6 weeks and 18 weeks of treatment ]
    Changes in the daily dose of fasting blood glucose from baseline

  4. Fasting C-Peptide [ Time Frame: 18 weeks of treatment ]
    Changes in the daily dose of fasting C-Peptide from baseline


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1.In accordance with the World Health Organization (WHO) issued in 1999 diabetes diagnostic criteriaType 2 diabetes mellitus (T2DM);
  • 2. Male or female patients ≥18 years old;
  • 3, BMI≥18.5 Kg/m2, < 35 Kg/m2;
  • 4, Glycosylated hemoglobin (HbA1C) > 7.5%; ≤10.5%;
  • 5, Stable dose (insulin daily therapeutic dose change within ±20%) of glycerine or DI The therapeutic dose of Terterigu or NPH basal insulin is ≥0.25IU/kg/ day/or 20IU/ day；
  • 6, Stable basic insulin treatment combined with metformin (metformin dose ≥1000mg/Days or maximum tolerated dose) ≥3 months；
  • 7. Voluntarily sign informed consent and agree to be randomly assigned to any experimental group.

Exclusion Criteria:

  • 1, Type 1 diabetes or specific type diabetes;
  • 2. Fasting blood glucose (FPG) exceeding 13.3 mmol/L (240 mg/dL);
  • 3, refractory hypertension [that is, on the basis of improving lifestyle, the application of a reasonable and tolerable sufficient amount of 3 or more antihypertensive drugs (including diuretics) for more than 1 month still does not reach the standard, or take 4 or more antihypertensive drugs to effectively control blood pressure];
  • 4. Triglyceride (TG) > 500 mg /dL (5.65 mmol/L);
  • 5, is taking or in the last 1 month has taken fibrate drug treatment;
  • 6, lower limb edema or general edema;
  • 7. Experienced 3 or more episodes of severe hypoglycemia and/or unintentional hypoglycemia in the 6 months prior to screening;
  • 8. A definite diagnosis of osteoporosis or any other known bone disease;
  • 9. History of diabetic ketoacidosis, diabetic hyperglycemia hyperosmolar syndrome, lactic acidosis and other acute complications of diabetes;
  • 10. Severe microvascular complications (proliferative retinopathy; Urinary albumin/creatinine ratio &gt; 300 mg/g; Marked peripheral neuropathy, etc.);
  • 11. Large vascular lesions leading to hospital admission within 6 months before inclusion;
  • 12, The New York Heart Association (NYHA) defines congestive heart failure as grade III or IV
  • 13, significant liver and kidney dysfunction and systemic disease (significant liver dysfunction is defined as AST&gt; 2.5 times the upper limit of normal and/or ALT&gt; 2.5 times the upper limit of normal and/or total bilirubin &gt; 1.5 times the upper limit of normal value; Renal dysfunction was defined as moderate to severe renal insufficiency (eGFR&lt;60 ml/ (min*1.73m2)).
  • 14. Use of other hypoglycemic agents not specified in the inclusion criteria (thiazolidinediones, GLP-1RA, premixed or fast-acting insulin) in the current or 3 months prior to screening, with the exception of short-term treatment with additional insulin (a total of 7 days or less) for complications;
  • 15, pregnant or lactating women, women of childbearing age who are unable or unwilling to take adequate contraception;
  • 16. Participating in clinical trials of other drugs or medical devices during or within 3 months prior to screening;
  • 17. The investigator considers it inappropriate to participate in this clinical trial.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06007014


Locations
Layout table for location information
China, Guangdong
the First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510000
Sponsors and Collaborators
Yanbing Li
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Yanbing Li, Professor, Sun Yat-sen University
ClinicalTrials.gov Identifier: NCT06007014    
Other Study ID Numbers: HLi
First Posted: August 23, 2023    Key Record Dates
Last Update Posted: September 13, 2023
Last Verified: September 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Yanbing Li, Sun Yat-sen University:
Chiglitazar
T2DM
Randomised
Double-blind
Placebo Parallel Controlled
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases